FEB 13, 2019 1:30 PM PST

Precision Medicine for Mice: Digital Biomarkers Transforming Drug Discovery

C.E. Credits: RACE
Speakers
  • Chief Scientific Officer, Vium
    Biography
      Laura Schaevitz has more than 20 years of experience with In vivo animal studies. As Chief Scientific Officer at Vium, she oversees the development of animal models and draws upon her experiences as a molecular and behavioral neuroscientist to direct the application of Vium's digital metrics to the animal models. In past experiences, Laura utilized a broad spectrum of mouse models including transgenic and nutrition-induced models of neurodevelopmental disorders such as autism, schizophrenia, Rett syndrome, and blindsight. Laura received her PhD in Neuroscience at Stanford University in 2006.

    Abstract:

    Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an important part of the drug development process, currently preclinical studies do not always predict drug failure or success in the clinic. Limited predictive power is attributed to many factors including limited measurable parameters on a single animal, infrequent collection, and small sample sizes that are often captured under conditions that have the potential to alter the animal’s physiologic state and confound data interpretation. Digital biomarkers, captured continuously without handling, provide objective, sensitive, and clinically meaningful methods of monitoring disease and response to therapeutic interventions. This webinar reviews the the current state of digital biomarkers in preclinical studies and discusses the challenges and opportunities for more widespread adoption to improve translation of preclinical studies to the clinic.

    Learning Objectives: 

    1. Define digital biomarkers and current state in drug development
    2. Examine how high frequency capture of digital biomarkers provides objective, sensitive, and meaningful readouts of disease state and compound efficacy that may be more translatable to the clinic.
    3. Discuss challenges and opportunities for the future capture and analysis of digital biomarkers in preclinical studies


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    Loading Comments...
    Show Resources